Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25882893 | 0.85 | KDM4E (0.49) | DPP4DPP7ALDH1A1SMN1; SMN2 | |
| SCHEMBL23599577 | 0.82 | ALDH1A1 (0.41) | NR3C2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL21910398 | 0.81 | SIGMAR1 (0.48) | NR3C2DPP4DPP7ALDH1A1MEN1 | |
| SCHEMBL21831526 | 0.80 | ALDH1A1 (0.38) | NR3C2DPP4DPP7ALDH1A1MEN1 | |
| SCHEMBL25882915 | 0.78 | KMT2A (0.36) | ALDH1A1MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL25882920 | 0.77 | SIGMAR1 (0.33) | DPP4DPP7ALDH1A1SMN1; SMN2SLC6A3 | |
| SCHEMBL25882219 | 0.76 | SIGMAR1 (0.40) | DPP4DPP7ALDH1A1SMN1; SMN2SLC6A3 | |
| SCHEMBL25881977 | 0.76 | SIGMAR1 (0.40) | DPP4DPP7ALDH1A1SMN1; SMN2SLC6A3 | |
| SCHEMBL25882229 | 0.76 | SIGMAR1 (0.40) | DPP4DPP7ALDH1A1SMN1; SMN2SLC6A3 | |
| SCHEMBL25881984 | 0.76 | SIGMAR1 (0.40) | DPP4DPP7ALDH1A1SMN1; SMN2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | NR3C2 1324/4885DPP4 3722/4885DPP7 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.